Effectiveness of esophagectomy in patients with thoracic esophageal squamous cell carcinoma receiving definitive radiotherapy or concurrent chemoradiotherapy through intensity‐modulated radiation therapy techniques

Abstract

Esophagectomy can be beneficial in patients with TESCC after definitive CCRT, especially in those who have advanced-stage disease. Cancer 2017;123:2043-2053. © 2017 American Cancer Society.

Value and application of trimodality therapy or definitive concurrent chemoradiotherapy in thoracic esophageal squamous cell carcinoma

“…70,71 Hence, trimodality therapy, rather than surgery alone, could be more suitable for patients with advanced-stage (IIIA-IIIC) TESCC. The current results are compatible with those reported by Yen et al 1 In clinical practice, we suggest that surgery should be the first choice for patients who have early stage (I-IIB) TESCC, and trimodality therapy could be beneficial for the survival of those with advanced-stage (IIIA-IIIC) TESCC. Nevertheless, if the patient is operable, then trimodality therapy could be the best choice for advanced TESCC (IIIA-IIIC) ( Table 3 and Fig.…”

“…[61][62][63][64] In addition, most studies have considered that the prognosis of adenocarcinoma is more favorable than that of SCC. 1 In the current study, we investigated whether higher irradiation doses (6000 cGy) for TESCC are more effective for survival (Table 4 and Fig. 1 In the current study, we investigated whether higher irradiation doses (6000 cGy) for TESCC are more effective for survival (Table 4 and Fig.…”

“…In our study, alcohol consumption was a significant, independent predictor of a poor outcome in patients with TESCC who were receiving treatments. 1 In addition, a review from Duke University suggests no benefit from paclitaxelbased neoadjuvant CCRT over cisplatin. [45][46][47] Our results are also compatible with those from previous studies.…”

“…1,[25][26][27][28][29] Our protocols were reviewed and approved by the Institutional Review Board of Taipei Medical University(TMU-JIRB no. We enrolled patients who received a diagnosis of TESCC between January 1, 2006, and December 31, 2014.…”

“…1 The treatments for esophageal cancer also vary, depending on their location, such as in the cervical or thoracic portion of the esophagus or at the gastroesophageal (GE) junction, according to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology and findings from previous studies. 1 The treatments for esophageal cancer also vary, depending on their location, such as in the cervical or thoracic portion of the esophagus or at the gastroesophageal (GE) junction, according to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology and findings from previous studies.…”